MHRA: double emergency contraceptive dose in women taking enzyme inducers

Women needing levonorgestrel-containing emergency contraception must take twice the usual dose if they are using CYP3A4-inducing medicines, the MHRA has said.

Levonorgestrel-containing emergency contraception is available with or without a prescription. | SCIENCE PHOTO LIBRARY
Levonorgestrel-containing emergency contraception is available with or without a prescription. | SCIENCE PHOTO LIBRARY

Women seeking emergency contraception who have used medicines or herbal remedies that induce the CYP3A4 liver enzyme within the last 4 weeks should preferably use a non-hormonal emergency contraceptive, ie a copper IUD.

In women who are unable or unwilling to use a copper IUD, the usual dose of levonorgestrel should be doubled from 1.5mg to 3mg to compensate for the reduced plasma levonorgestrel levels caused by the enzyme inducer.

No increased risk of side-effects is expected from the increased dose of levonorgestrel in these circumstances.

Reduced contraceptive efficacy

Medicines that induce CYP3A4 increase the metabolism of levonorgestrel, which reduces the drug's levels in the blood and may compromise its contraceptive efficacy.

Elevated levels of CYP3A4 enzymes can persist for up to 4 weeks after cessation of an enzyme-inducing medicine.

CYP3A4 enzyme inducers include:

For women taking these medicines, healthcare professionals should provide advice on highly effective ongoing contraception that is not affected by hepatic enzyme-inducing drugs (guidance is available from the Faculty of Sexual and Reproductive Health). This is particularly important as some of the medicines have been associated with an increased risk of birth defects when taken during pregnancy.

Exclude pregnancy

Women should also be advised to have a pregnancy test to exclude pregnancy after taking levonorgestrel-containing emergency contraception, and to seek prompt medical advice if they do become pregnant.

The MHRA's updated advice is in line with the above-mentioned guidance from the Faculty of Sexual and Reproductive Health, and applies to both prescription and non-prescription supply of levonogestrel-containing emergency contraception.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more